Slm Stock News

SLM Corporation found using ticker (SLM) now have 11 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The target price ranges between 27 and 21 with the average target price sitting at 24.45. Now with the previous closing price of 19.88 this now indicates there is a potential upside of 23.0%. There is a 50 day moving average of 19.06 and the 200 day moving average is 18.97. The market capitalisation for the company is $5,522m. You can visit the company''s website by visiting: https://www.salliemae.com [stock_market_widget type="chart" symbol="SLM" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] The potential market cap would be $6,792m based on the market concensus. SLM Corporation, through its subsidiaries, originates and services private education loans to students and their families to finance the cost of their education in the United States. It also offers retail deposit accounts, including certificates of deposit, money market deposit accounts, and high-yield savings accounts; and omnibus accounts.

NEWARK, Del.--(BUSINESS WIRE)--Sallie Mae® (Nasdaq: SLM) today announced CEO Jon Witter will speak at the Credit Suisse Financial Services Forum on Thursday, Feb. 17, at 3:30 p.m. ET. A live audio we

While a higher fee income drives Sallie Mae's (SLM) Q4 results, muted net interest income and increased expenses act as spoilsports.

While a higher fee income drives Sallie Mae's (SLM) Q4 results, muted net interest income and increased expenses act as spoilsports.

SLM Corp's (SLM) CEO Jon Witter on Q4 2021 Results - Earnings Call Transcript

Sallie Mae (SLM) delivered earnings and revenue surprises of 3.96% and 3.81%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

SLM Corporation PFD SER B (SLMBP) declares $0.47772/share quarterly dividend, 3.9% increase from prior dividend of $0.4596. Forward yield 3.27%

After losing some value lately, a hammer chart pattern has been formed for Sallie Mae (SLM), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revis

Sallie Mae (SLM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NEWARK, Del.--(BUSINESS WIRE)--Sallie Mae® (Nasdaq: SLM) will release fourth-quarter and full-year 2021 financial results after market close on Wednesday, Jan. 26, 2022. The earnings release will be

Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available on Seeking Alpha, iTunes, Stitcher and Spotify. U.S.

Catching COVID-19 could impact fertility for weeks after recovery from the virus, according to a new study which looked at sperm quality in Belgian patients who suffered symptomatic coronavirus infections. Semen samples from 35 men taken within a month of their recovery showed a 60 per cent drop in their sperm''s ability to move and a 37 per cent reduction in sperm count. The study, published on Monday in the Fertility and Sterility journal, took samples from 120 men in Belgium with an average age of 35 years and at an average of 52 days after their COVID-19 symptoms had cleared. As time since recovery from COVID-19 increased, the quality of sperm also improved. Samples from 51 patients taken between one and two months after recovery showed 37 per cent had reduced sperm motility and 29 per cent had low sperm counts, falling further to 28 per cent and 6 per cent after at least two months had passed. The researchers also said they had found "strong evidence" that COVID-19 could not be sexually transmitted through semen after a person had recovered from illness.

Sinopharm vaccine have the least antibody response after three months compare to other vaccines, the latest antibody response for vaccines study done by a Sri Lankan research team shows. An antibody response research done by the Allergy Immunology and Cell Biology unit of University of Sri Jayewardenepura has shown that the antibody response was seen highest in the Moderna vaccine followed by Sputnik V, AstraZeneca, Sputink V light (first dose then) and then Sinopharm. The ACE2 blocking antibody levels were highest to lowest was Moderna > Sputnik V/ Oxford AstraZeneca (had equal levels)> first dose of Sputnik V (Sputnik light) > Sinopharm, the study said. Sinopharm is the most widely used vaccine in Sri Lanka which is generally believed to have contributed to lower levels of hospitalization and deaths, but its usefulness declines over time faster than others used in the country. In Sri Lanka recipients of all vaccines are being urged to get the Pfizer as a third booster which the government has made available.